Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL27145923 | 0.90 | — | — | |
| Acetic Acid SCHEMBL8328631 | 0.89 | — | — | |
| Acetic Acid SCHEMBL9564747 | 0.89 | FFAR3 (0.88) | — | |
| Acetic Acid SCHEMBL712 | 0.89 | — | — | |
| Acetic Acid SCHEMBL1230066 | 0.89 | FFAR3 (0.88) | — | |
| Acetic Acid SCHEMBL3432477 | 0.89 | FFAR3 (0.88) | — | |
| Acetic Acid SCHEMBL28308127 | 0.89 | — | — | |
| Tetrafluoroethylene SCHEMBL28004090 | 0.86 | FFAR3 (0.64) | — | |
| Acetic Acid SCHEMBL31214327 | 0.84 | — | — | |
| Acetic Acid SCHEMBL28221982 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| US-4304765-A | Ocular insert housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1981-12-08 | — | — | US | claimed |
| WO-2025227057-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING IMMUNE-RELATED ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITOR TREATMENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20240150836-A1 | METHODS OF PREDICTING AND TREATING IMMUNOTHERAPY TOXICITY BASED ON IMMUNE CELL POPULATIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | disclosed |
| CN-116553578-A | Surface modified manganese-based Prussian white material, preparation method thereof and application of sodium ion battery | 浙江宇钠科技有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-116443895-A | Manganese-based Prussian white material, preparation method and application thereof in sodium ion battery | 浙江宇钠科技有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20220054417-A1 | DELIVERY OF AGENTS TO INFLAMED TISSUES USING FOLATE-TARGETED LIPOSOMES | PURDUE RESEARCH FOUNDATION (US) | 2022-02-24 | — | — | US | disclosed |
| US-11185505-B2 | Delivery of agents to inflamed tissues using folate-targeted liposomes | PURDUE RESEARCH FOUNDATION (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200297632-A1 | DELIVERY OF AGENTS TO INFLAMED TISSUES USING FOLATE-TARGETED LIPOSOMES | PURDUE RESEARCH FOUNDATION (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200253871-A1 | LIPOSOMAL CORTICOSTEROIDS FOR TREATMENT OF INFLAMMATORY DISORDERS IN HUMANS | LAURENTIA HOLDING B.V. (NL) | 2020-08-13 | — | — | US | disclosed |
| WO-2004019916-A1 | VESICLE-ENCAPSULATED CORTICOSTEROIDS FOR THE TREATMENT OF CANCER | UNIVERSITEIT UTRECHT (NL) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004019914-A1 | LIPID-POLYMER-CONJUGATES COMPOSITIONS COMPRISING CORTICOSTEROIDS FOR THE TREATMENT OF CANCER | YAMANOUCHI EUROPE B.V. (NL) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004019915-A1 | VESICLE-ENCAPSULATED CORTICOSTEROIDS FOR THE TREATMENT OF CANCER | YAMANOUCHI EUROPE B.V. (NL) | 2004-03-11 | — | — | WO | disclosed |
| EP-1393720-A1 | Vesicle-encapsulated corticosteroids for treatment of cancer | Universiteit Utrecht (NL) | 2004-03-03 | — | — | EP | disclosed |
| US-20040037875-A1 | Composition for treatment of inflammatory disorders | ENCELADUS PHARMACEUTICALS B.V. (NL) | 2004-02-26 | — | — | US | disclosed |
| WO-2003105805-A1 | COMPOSITION FOR TREATMENT OF INFLAMMATORY DISORDERS | UNIVERSITEIT UTRECHT HOLDING B.V. (NL) | 2003-12-24 | — | — | WO | disclosed |
| EP-1371362-A1 | Composition for treatment of inflammatory disorders | Universiteit Utrecht Holding B.V. (NL) | 2003-12-17 | — | — | EP | disclosed |
| EP-1347743-A2 | COMPOSITION FOR TREATMENT OF INFLAMMATORY DISORDERS | Universiteit Utrecht Holding B.V. (NL) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002045688-A2 | COMPOSITION FOR TREATMENT OF INFLAMMATORY DISORDERS | UNIVERSITEIT UTRECHT HOLDING B.V. (NL) | 2002-06-13 | — | — | WO | disclosed |